Claims
- 1. A composition of Chinese medicine comprising Radix angelica sinensis (DangGui) 15-60%, Ligusticum chuanxiong (ChuanXiong) 5-20%, Hirudo (ShuiZhi) 3-7%, Polygonatum sibiricum (HuangJing) 4-15%.
- 2. The composition of claim 1, further comprising Glycyrrhiza uralensis (Gancao) at the weight ratio 1.5-3.5%.
- 3. The composition of claim 1, wherein Ligusticum chuanxiong (ChuanXiong) is replaced by one of the following: Carthamus timctorius (Hong Hua) or Prunus persica (Tao Ren) or Achyrantes bidentata (Huai Nuxi) without changing its weight ratio in the formulation.
- 4. The composition of claim 1, wherein Polygonatum sibiricum (HuangJing) 4-15% is supplemented by one or combination thereof the following ingredients in the weight ratio indicated: Lycium Chinense mill (GouQiZi) 3-5%, Curculigo orchioides (XianMao) 3-5%, epimedium grandiflorum (YinYangHuo) 2-5%, plastrum testudinis (ShengGuiBan) 4-6%, Cornus officinalis (ShanZhuYu) 2-5%, Psoralea corylifolia (BuGuZhi) 3-5%, Leonurus heterophyllus (YiMuCao) 5-10%.
- 5. The composition of claim 1, wherein Paeonia rubrae (Chishao) 5-10% is added to the formula.
- 6. The composition of claim 5, wherein Paeonia rubrae (Chishao) is replaced by one of the following, Paeonia lactiflora (Bai shao) or Gelatinum corii Asini (E Jiao) without changing its weight ratio in the formulation.
- 7. The composition of claim 1, further comprising Psoralea corylifolia (BuGuZhi) 3-5%.
- 8. The composition of claim 7, wherein Psoralea corylifolia (BuGuZhi) is replaced by one of the following, Cuscuta chinensis (TuSiZi), Semen Astragali Complanati (ZhongJiLi) or Eucommia ulmoidis (Duzhong) without changing its weight ratio in the formulation.
- 9. The composition of claim 1, further comprising Astragalus membranaceus (HuangQi) at weight ratio 7-20%.
- 10. The composition of claim 9, wherein Astragalus membranaceus (HuangQi) is replaced by one of the following, Radix codonopsis pilosulae (Dang Shen), Radix Ginseng (Ren Shen) without changing its weight ratio in the formulation.
- 11. A pharmaceutical composition for the treatment of neuronal injuries of all causes and neurodegenerative diseases comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 12. A method for the treatment of neuronal injuries of all causes and neurodegenerative diseases in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 11.
- 13. A pharmaceutical composition for the treatment of feeblemindedness or mental retardation comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 14. A method for the treatment of feeblemindedness or mental retardation in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 13.
- 15. A pharmaceutical composition for the treatment of cerebral palsies comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 16. A method for the treatment of cerebral palsies in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 15.
- 17. A pharmaceutical composition for the treatment of paralysis resulting from all causes comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 18. A method for the treatment of paralysis resulting from all causes in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 17.
- 19. A pharmaceutical composition for the treatment of paralysis caused by head or spinal cord injuries comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 20. A method for the treatment of paralysis caused by head or spinal cord injuries in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 19.
- 21. A pharmaceutical composition for the treatment of motor neuron disease comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 22. A method for the treatment of motor neuron disease in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 21.
- 23. A pharmaceutical composition for the treatment of dementia of all causes comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 24. A method for the treatment of dementia of all causes in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 23.
- 25. A pharmaceutical composition for the treatment of dementia caused by infectious agents comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 26. A method for the treatment of dementia caused by infectious agents in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 25.
- 27. A pharmaceutical composition for the treatment of encephalopathy of all causes of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 28. A method for the treatment of encephalopathy of all causes in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 27.
- 29. A pharmaceutical composition for the treatment of cerebral atrophy comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 30. A method for the treatment of cerebral atrophy in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 29.
- 31. A pharmaceutical composition for the treatment of oliverpontocerebellar atrophy comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 32. A method for the treatment of oliverpontocerebellar atrophy in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 31.
- 33. A pharmaceutical composition for the treatment of ataxia of all causes comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 34. A method for the treatment of ataxia in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 33.
- 35. A pharmaceutical composition for the treatment of vegetative state of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 36. A method for the treatment of vegetative state in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 35.
- 37. A pharmaceutical composition for the treatment of sequel of apoplexy of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 38. A method for the treatment of sequel of apoplexy in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 37.
- 39. A pharmaceutical composition for the treatment of all autoimmune diseases and all autoimmune conditions of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 40. A method for the treatment of all autoimmune diseases and all autoimmune conditions in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 39.
- 41. A pharmaceutical composition for the treatment of multiple sclerosis (MS) of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 42. A method for the treatment of multiple sclerosis (MS) in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 41.
- 43. A pharmaceutical composition for the treatment of myelitis of all types of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 44. A method for the treatment of myelitis of all types in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 43.
- 45. A pharmaceutical composition for the treatment of polyneuritis of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 46. A method for the treatment of polyneuritis in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 45.
- 47. A pharmaceutical composition for the treatment of muscle stiffness resulting of all causes (including congenital muscle-stiffness) of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 48. A method for the treatment of muscle stiffness resulting of all causes (including congenital muscle-stiffness) in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 47.
- 49. A pharmaceutical composition for the treatment of muscle spasm of all causes of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 50. A method for the treatment of muscle spasm of all causes in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 49.
- 51. A pharmaceutical composition for the treatment of arteritis of a subject comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 52. A method for the treatment arteritis in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 51.
- 53. A pharmaceutical composition for the treatment or alleviating inflammatory or allergic reactions comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 54. A method for the treatment or alleviating inflammatory or allergic reactions in a subject by administrating to the subject an effective amount of the pharmaceutical composition of claim 53.
- 55. A pharmaceutical composition for reducing the viscosity of blood and plasma comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 56. A method for reducing the viscosity of blood and plasma in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 55.
- 57. A pharmaceutical composition for inhibiting platelet aggregation and for de-aggregating the already formed platelet aggregation comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 58. A method for inhibiting platelet aggregation and for de-aggregating the already formed platelet aggregation in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 57.
- 59. A pharmaceutical composition for improving blood circulation, microcirculation of the body comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 60. A method for improving blood circulation, microcirculation of the body in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 59.
- 61. A pharmaceutical composition for improving brain blood flow comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 62. A method for improving brain blood flow in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 61.
- 63. A pharmaceutical composition for immunoregulation comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 64. A method for immunoregulation in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 63.
- 65. A pharmaceutical composition for inhibiting delayed-type hypersensitivity (DTH) comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 66. A method for inhibiting delayed-type hypersensitivity (DTH) in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 65.
- 67. A pharmaceutical composition for increasing post-immunization antibody production comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 68. A method for increasing post-immunization antibody production in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 67.
- 69. A pharmaceutical composition for promoting regeneration of damaged neurons and other cells comprising effective amount of the composition of claim 1-10 and a pharmaceutically acceptable carrier.
- 70. A method for promoting regeneration of damaged neurons and other cells in a subject comprising administrating to the subject an effective amount of the pharmaceutical composition of claim 69.
Parent Case Info
[0001] This application claims priority of U.S. Ser. No. 60/253,013, filed Nov. 22, 2000, the contents of which are hereby incorporated into this application by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60253013 |
Nov 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/IB01/02859 |
Nov 2001 |
US |
Child |
10442865 |
May 2003 |
US |